Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 06, 2021 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Provides 2021 Financial Guidance

– Xtampza® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA...
November 05, 2020 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020

– Strengthened Formulary Access for Xtampza® ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of...
October 26, 2020 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza® ER” in Pain Medicine

STOUGHTON, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
October 22, 2020 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday,...
September 30, 2020 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Settlement with Teva Resolving Xtampza® ER Patent Litigation

STOUGHTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
September 25, 2020 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Appoints Rita Balice-Gordon to its Board of Directors

STOUGHTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
September 14, 2020 08:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference

STOUGHTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
September 09, 2020 16:05 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference

STOUGHTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management,...
August 05, 2020 16:01 ET | Source: Collegium Pharmaceutical, Inc.

Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020

– Non-GAAP Net Income of $33.2 Million in the Second Quarter of 2020 – – Generated $43.9 Million in Cash from Operating Activities in the Second Quarter of 2020 – – Xtampza ® ER Net Revenue...
July 21, 2020 17:00 ET | Source: Collegium Pharmaceutical, Inc.

Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

STOUGHTON, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday,...